|
APBB2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.07025499573865E-13 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.18935980456081E-13 |
| Normal-vs-Stage2 |
1.30930000175056E-08 |
| Normal-vs-Stage3 |
3.80806497446429E-14 |
| Normal-vs-Stage4 |
1.22124532708767E-15 |
| Stage1-vs-Stage2 |
1.879600E-01 |
| Stage1-vs-Stage3 |
3.027800E-01 |
| Stage1-vs-Stage4 |
1.502420E-02 |
| Stage2-vs-Stage3 |
7.345900E-02 |
| Stage2-vs-Stage4 |
1.085520E-02 |
| Stage3-vs-Stage4 |
1.964040E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.28785870856518E-13 |
| Normal-vs-AfricanAmerican |
2.3521999999998E-06 |
| Normal-vs-Asian |
5.295763827462E-14 |
| Caucasian-vs-AfricanAmerican |
2.526000E-01 |
| Caucasian-vs-Asian |
2.981200E-01 |
| AfricanAmerican-vs-Asian |
8.232200E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.3855583347322E-13 |
| Normal-vs-Female |
1.74604775082798E-12 |
| Male-vs-Female |
8.161200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.04058991926104E-13 |
| Normal-vs-Age(41-60Yrs) |
1.65534252971611E-13 |
| Normal-vs-Age(61-80Yrs) |
1.72206693349608E-12 |
| Normal-vs-Age(81-100Yrs) |
4.424600E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.844600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.458000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.194400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.501800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.314000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.895200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.976300E-03 |
| Classical-VS-Follicular |
4.868600E-01 |
| Classical-VS-Other |
6.924200E-01 |
| Classical-VS-Normal |
2.68796096491997E-12 |
| Tall-VS-Follicular |
6.063900E-03 |
| Tall-VS-Other |
3.664800E-01 |
| Tall-VS-Normal |
4.10782519111308E-15 |
| Follicular-VS-Other |
5.999000E-01 |
| Follicular-VS-Normal |
1.06199493643544E-11 |
| Other-VS-Normal |
5.383600E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.76414438612937E-13 |
| Normal-vs-N1 |
1.64601665630926E-12 |
| N0-vs-N1 |
1.169250E-01 |
|
|
